Form 4: Travere Therapeutics Director Ron Squarer Reports Acquisition and Disposal of Common Stock and Stock Options

Director Ron Squarer reports acquisition of 6,500 shares of common stock and 19,500 stock options, along with the disposal of 6,500 shares.

Summary

• On May 15, 2025, Ron Squarer, a director of Travere Therapeutics, Inc., reported transactions involving the company's securities.
• Squarer acquired 6,500 shares of common stock through an automatic equity grant under the company's 2018 Equity Incentive Plan.
• He also acquired 19,500 stock options with an exercise price of $21.15, vesting over one year and expiring on May 15, 2035.
• Additionally, Squarer disposed of 6,500 shares of common stock.
• Following these transactions, Squarer directly owns 35,375 shares of common stock and 19,500 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a standard compensation plan, with both acquisitions and disposals reported. It doesn't strongly indicate positive or negative sentiment.

Positives

• The acquisition of stock options and common stock by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 6,500 shares could be interpreted negatively, although it's important to consider the context of the overall transactions.

Risks

• The vesting schedule of the stock options means the director's incentives are aligned with the company's performance over the next year.
• Market conditions and company performance could impact the value of the stock options and common stock.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options suggests a focus on the company's performance over the next year.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's confidence in the company.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they interpret the director's actions.

Key Dates

Keywords

Travere Therapeutics, Director, Ron Squarer, Stock Options, Common Stock, Equity Incentive Plan, Beneficial Ownership, Form 4, TVTX